Silver-catalyzed intramolecular hydroamination of alkynes in aqueous media: efficient and regioselective synthesis for fused benzimidazoles
作者:Xu Zhang、Yu Zhou、Hengshuai Wang、Diliang Guo、Deju Ye、Yungen Xu、Hualiang Jiang、Hong Liu
DOI:10.1039/c0gc00668h
日期:——
A simple, convenient and green synthetic approach to diverse fused tricyclic benzimidazoles has been developed by Ag(I) complex catalyzed intramolecular hydroamination under the classic method or by microwave irradiation in water. This strategy presents an operationally simple and environmentally friendly transformation, in which various substituted benzimidazoles facilitated efficient cyclization
Wittig Rearrangements of Boron-Based Oxazolidinone Enolates
作者:Zirong Zhang、David B. Collum
DOI:10.1021/acs.joc.9b01426
日期:2019.9.6
[2,3]-Sigmatropic rearrangements (Wittig rearrangements) of α-alkoxy oxazolidinone enolates are described. Whereas alkali metal enolates fail, owing to facile deacylation, boron enolates generated from di-n-butylboron triflate and triethylamine rearranged in good yields and high selectivities with exceptions noted. IR and NMR spectroscopies show the boron is chelated by the α-alkoxy group rather than
(METHYLSULFONYL)PHENYL-2-(5H)-FURANONES WITH OXYGEN LINK AS COX-2 INHIBITORS
申请人:Merck Frosst Canada & Co.
公开号:EP0970067B1
公开(公告)日:2003-07-02
US6071954A
申请人:——
公开号:US6071954A
公开(公告)日:2000-06-06
[EN] (METHYLSULFONYL)PHENYL-2-(5H)-FURANONES WITH OXYGEN LINK AS COX-2 INHIBITORS<br/>[FR] (METHYLSUFONYL)PHENYL-2-(5H)-FURANONES A LIAISON OXYGENE, UTILISES COMME INHIBITEURS DE CYCLO-OXYGENASE-2
申请人:MERCK FROSST CANADA & CO.
公开号:WO1998041516A1
公开(公告)日:1998-09-24
(EN) The invention encompasses the novel compound of Formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula (I).(FR) L'invention concerne un composé nouveau représenté par la formule (I), utilisé dans le traitement de maladies à médiation par cyclo-oxygénase-2. L'invention se rapporte également à certaines compositions pharmaceutiques qui sont destinées au traitement de maladies à médiation par cyclo-oxygénase-2 et qui contiennent des composés de formule (I).